glp-1 and type 1 diabetes GLP-1-based therapies for 2 diabetes: from single, dual triple agonists to endogenous production and L-cell differentiation | Diabetology & Metabolic Syndrome Can GLP-1 medications be beneficial

State Medicaid Coverage of GLP-1s for Obesity Treatment (as of August 2024) KFF found that as of August 2024, 13 state Medicaid programs covered GLP-1s for obesity treatment within their fee-for-service programs

While immunotherapy has been groundbreaking in the treatment of stage 4 colorectal cancer, only about 15% of patients are found to be eligible for the treatment based on their protein screenings, Dr

When -MSH binds to MC4R neurons in the paraventricular nucleus (PVN) of the hypothalamus, it induces a signalling cascade that ultimately results in decreased appetite

Human studies

WHO CAN TAKE SEMAGLUTIDE

Pioglitazone does not induce hypoglycaemia episodes, it improves the lipid profile and has demonstrated certain cardiovascular benefits and a renoprotective effect in CKD patients.81 Its use is associated with sodium and water retention, oedema and an increased risk of heart failure,82 limiting its use in CKD patients